This clinical trial is focused on studying a type of cancer known as esophageal adenocarcinoma, which is a form of esophageal cancer. The study is investigating the use of a medication called tocilizumab, which is also known by other names such as RO4877533 and BIIB800. Tocilizumab is administered through an intravenous route, meaning it is given directly into a vein. The purpose of this study is to see if targeting certain cells in the body, called stromal cells, with tocilizumab can improve the effectiveness of standard cancer treatments like chemotherapy and radiation therapy.
Participants in the study will receive either tocilizumab or a placebo, in addition to their regular cancer treatment. The study will monitor how well the cancer responds to the treatment by looking at changes in the tumor tissue. This will help researchers understand if tocilizumab can make the standard treatment more effective. The study will also look at other factors, such as the rate of successful tumor removal through surgery and the overall survival of participants.
Throughout the study, researchers will collect information on the safety of tocilizumab, including any side effects or complications that may arise. They will also measure certain proteins and genes in the blood and tumor tissue to understand how tocilizumab works in the body. The study aims to provide valuable insights into whether tocilizumab can be a beneficial addition to the treatment of esophageal adenocarcinoma.
The Netherlands 